Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
58.26
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3
Open
58.26
Bid (Size)
58.15 (13)
Ask (Size)
58.18 (10)
Prev. Close
58.26
Today's Range
58.26 - 58.26
52wk Range
42.63 - 58.97
Shares Outstanding
1,250,690,553
Dividend Yield
3.27%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from...
Via
Benzinga
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
September 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+16.52%
+16.52%
1 Month
+6.35%
+6.35%
3 Month
+24.35%
+24.35%
6 Month
+22.06%
+22.06%
1 Year
+5.54%
+5.54%
More News
Read More
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
Via
The Motley Fool
NASDAQ:SNY may be ready to breakout.
August 12, 2024
Via
Chartmill
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
Via
MarketBeat
Topics
ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
Via
Benzinga
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Despite its impressive fundamentals, NASDAQ:SNY remains undervalued.
September 10, 2024
Via
Chartmill
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
Via
Benzinga
Exposures
Product Safety
Why Sanofi Stock Was Robustly Healthy Today
September 03, 2024
Via
The Motley Fool
Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
September 03, 2024
Via
Benzinga
European Stocks Little Moved On Labor Day, German DAX Mark Record Close, Natural Gas Futures Rise: What's Driving Markets Monday?
September 02, 2024
Via
Benzinga
Topics
Energy
Exposures
Fossil Fuels
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
August 26, 2024
Via
Benzinga
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
August 24, 2024
Via
The Motley Fool
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
August 20, 2024
Via
Benzinga
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
August 19, 2024
Via
Investor's Business Daily
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
August 19, 2024
Via
Chartmill
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
August 16, 2024
Via
Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
August 15, 2024
Via
InvestorPlace
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
August 14, 2024
Via
Investor's Business Daily
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
August 12, 2024
Via
MarketBeat
Exposures
COVID-19
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
August 09, 2024
Via
Benzinga
Exposures
Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
August 08, 2024
Via
Investor Brand Network
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
August 08, 2024
Via
Benzinga
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.